The healthcare community is buzzing by retatrutide, a new dual GIP and GLP-1 target that’s showing impressive results in clinical trials . This medication works by mimicking natural hormones to affect appetite and promote feelings of satiety, ultimately leading noticeable body reduction . While currently under review and not broadly available, in